The current study showed that the RFS and OS in the surgery + TACE subgroup in the Ki67 high expression group were greater than the surgery subgroup, while there was no statistical difference between the two subgroups in the Ki67 low expression group, suggesting that the tumor Ki67 level can be used as a criterion for performing PA-TACE after radical liver tumor resection and screen suitable patients for effective anti-relapse treatment. The gene discussed is MKI67; the disease is neoplasm.